Effect of Motor Cognitive Interference on Cognition and Quality of Life on Patients with Multiple Sclerosis

February 17, 2025 updated by: Ahmed Abd El Aziz, Cairo University

Effect of Motor Cognitive Interference on Cognition and Quality of Life on Multiple Sclerosis Patients

Is there an effect of Cognitive Motor Interference on Cognition and quality of life on Multiple Sclerosis patients.

Study Overview

Status

Active, not recruiting

Conditions

Intervention / Treatment

Detailed Description

we will assess the effectiveness of Cognitive Motor interference on Cognition and quality of life on Multiple Sclerosis patients

Study Type

Interventional

Enrollment (Actual)

44

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Egypt
    • Dokki
      • Giza, Dokki, Egypt, 11732
        • Faculty of Physical Therapy Cairo University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  1. M S patients complain of Mild Cognitive impairment according to Modified Mini Mental State (MMSE).
  2. Patients with remission and relapse, primary and secondary progression types of MS.
  3. Age between 25 and 45 years.
  4. Patients from both gender.

Exclusion Criteria:

  1. patients have visual disorders
  2. patients have auditory disturbance
  3. Non educational patients.
  4. Patients with psychiatric disorders.
  5. Patients with mod to severe cognitive impairment according to MMSE

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Study group
Study group will uses Cognitive Motor Interference
Behavioral: Cognitive Motor Interference
Dual task that uses cognitive in addition to Motor training
Active Comparator: Control group will uses traditional physical therapy
control group will use traditional physiotherapy
Behavioral: traditional physical therapy
physiotherapy program including exercises in addition to physical modalities

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Cognition (working memory and divided attention)
Time Frame: baseline assessment and after 12 sessions of Cognitive motor interference 3 sessions per weak for 4 weaks
cognition domains including working memory and divided attention will be assessed by rehacom V 6.10.2.0 software
baseline assessment and after 12 sessions of Cognitive motor interference 3 sessions per weak for 4 weaks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
A health-related quality of life
Time Frame: Baseline assessment and after 12 sessions of Cognitive motor interference 3 sessions per weak for 4 weaks
quality of life will be assessed by Multiple Sclerosis Quality of Life (MSQOL)-54 Instrument
Baseline assessment and after 12 sessions of Cognitive motor interference 3 sessions per weak for 4 weaks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Cairo University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 10, 2024

Primary Completion (Estimated)

June 12, 2025

Study Completion (Estimated)

August 1, 2025

Study Registration Dates

First Submitted

December 16, 2024

First Submitted That Met QC Criteria

February 17, 2025

First Posted (Actual)

March 25, 2025

Study Record Updates

Last Update Posted (Actual)

March 25, 2025

Last Update Submitted That Met QC Criteria

February 17, 2025

Last Verified

February 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • P.T>REC/012/005458

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe